741 related articles for article (PubMed ID: 15937767)
1. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J; Munsiff SS; Driver CR; Sackoff J
Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
[TBL] [Abstract][Full Text] [Related]
2. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
[TBL] [Abstract][Full Text] [Related]
3. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR
Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259
[TBL] [Abstract][Full Text] [Related]
5. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.
Li J; Munsiff SS; Tarantino T; Dorsinville M
Int J Infect Dis; 2010 Apr; 14(4):e292-7. PubMed ID: 19656705
[TBL] [Abstract][Full Text] [Related]
6. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
Burman W; Benator D; Vernon A; Khan A; Jones B; Silva C; Lahart C; Weis S; King B; Mangura B; Weiner M; El-Sadr W;
Am J Respir Crit Care Med; 2006 Feb; 173(3):350-6. PubMed ID: 16109981
[TBL] [Abstract][Full Text] [Related]
7. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City.
Driver CR; Munsiff SS; Li J; Kundamal N; Osahan SS
Clin Infect Dis; 2001 Nov; 33(10):1762-9. PubMed ID: 11595988
[TBL] [Abstract][Full Text] [Related]
8. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
9. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
Jenny-Avital ER; Joseph K
Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.
Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA
N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
[TBL] [Abstract][Full Text] [Related]
12. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
[TBL] [Abstract][Full Text] [Related]
13. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Mar; 49(9):185-9. PubMed ID: 11795500
[TBL] [Abstract][Full Text] [Related]
14. Determinants of drug-resistant tuberculosis: analysis of 11 countries.
Espinal MA; Laserson K; Camacho M; Fusheng Z; Kim SJ; Tlali RE; Smith I; Suarez P; Antunes ML; George AG; Martin-Casabona N; Simelane P; Weyer K; Binkin N; Raviglione MC
Int J Tuberc Lung Dis; 2001 Oct; 5(10):887-93. PubMed ID: 11605880
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.
Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW
Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387
[TBL] [Abstract][Full Text] [Related]
16. Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults.
Wilson D; Nachega J; Morroni C; Chaisson R; Maartens G
Int J Tuberc Lung Dis; 2006 Jan; 10(1):31-8. PubMed ID: 16466034
[TBL] [Abstract][Full Text] [Related]
17. A continuing survey of drug-resistant tuberculosis, New York City, April 1994.
Fujiwara PI; Cook SV; Rutherford CM; Crawford JT; Glickman SE; Kreiswirth BN; Sachdev PS; Osahan SS; Ebrahimzadeh A; Frieden TR
Arch Intern Med; 1997 Mar; 157(5):531-6. PubMed ID: 9066457
[TBL] [Abstract][Full Text] [Related]
18. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
20. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients.
Pulido F; Peña JM; Rubio R; Moreno S; González J; Guijarro C; Costa JR; Vázquez JJ
Arch Intern Med; 1997 Jan; 157(2):227-32. PubMed ID: 9009982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
